Opinion|Videos|August 23, 2024
Logistical and Access Challenges with CAR T-cell Therapy in R/R ALL
Experts in acute lymphoblastic leukemia examine the logistical challenges associated with CAR T-cell therapy delivery and assess the frequency of patient attrition due to manufacturing delays.
Advertisement
Video content above is prompted by the following:
- What are some logistical barriers with delivery of CAR T-cell Therapy?
- How frequently do your patients have to drop out from CAR T-cell therapy due to manufacturing time? How does it compare to the rates in the ZUMA-3 and FELIX Study?
- How feasible is it for your patients to remain in close proximity to the hospital per the REMS requirements?
- Have you observed any additional or unique access challenges in minority populations?
Advertisement
Related to this article
Peter Voorhees, MD, discusses the integration of CAR T-cell therapy in early-relapsed myeloma and the importance of early T-cell–redirecting therapy use.
Peter WT Pisters, MD, MHCM, will retire as president of The University of Texas MD Anderson Cancer Center.
The FDA has granted fast track designation to varsetatug masetecan for relapsed/refractory metastatic colorectal cancer.
SYS6090, a first-in-class PD-1/IL-15 bispecific fusion protein, earned fast track status for MSS/pMMR metastatic colorectal cancer that has progressed on standard systemic therapy.
Cathy Eng, MD, FACP, FASCO, discusses how oncology fellows can navigate the journal submission and review process.
ASCO issued an alert regarding dwindling supplies of ifosfamide, which is used across testicular cancer and sarcoma regimens.
The WVU Heart and Vascular Institute and WVU Cancer Institute performed West Virginia’s first single-port robotic-assisted thoracoscopic lobectomy.
The FDA approval of daraxonrasib was based on data from the phase 3 RASolute 302 trial in previously treated metastatic pancreatic ductal adenocarcinoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daraxonrasib for Metastatic Pancreatic Ductal Adenocarcinoma
2
Dr Reiss Binder on the FDA Approval of Daraxonrasib for Metastatic PDAC
3
FDA Grants Fast Track Designation to Varsetatug Masetecan for Relapsed/Refractory Metastatic Colorectal Cancer
4
ASCO Issues Warning Regarding Ifosfamide Shortage for Cancer Care
5